Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Key Highlights
- ➤DMRA granted options for 144,400 ordinary shares to five newly hired employees
- ➤Options carry a $21.28 exercise price and 10-year term
- ➤Options vest 25% after one year, then monthly over 36 months
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to five newly-hired, non-executive employees on October 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grants consist of options to purchase an aggregate of 144,400 Damora ordinary shares with a 10-year term and an exercise price of $21.28 per share. All of the options vest as to 25% on the first anniversary of the employees’ start date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan, and the terms and conditions of an option award agreement.
Get started
Create a free account to read the full story.